Paclitaxel-encapsulated core-shell nanoparticle of cetyl alcohol for active targeted delivery through oral route.
Debabrata Ghosh DastidarAmlan DasSatabdi DattaSuvranil GhoshMahadeb PalNeeraj Singh ThakurUttam C BanerjeeGopal ChakrabartiPublished in: Nanomedicine (London, England) (2019)
Aim: Paclitaxel (PTX) has no clinically available oral formulations. Cetyl alcohol is metabolized by alcohol dehydrogenase and aldehyde dehydrogenase that are overexpressed in cancer cells. So, PTX-encapsulated core-shell nanoparticle of cetyl alcohol (PaxSLN) could target the cancer cells through oral route. Materials & methods: PaxSLN was synthesized using microemulsion template. Efficiency of PaxSLN was evaluated by ALDEFLUOR™, multicellular tumor spheroid formation inhibition assays and CT26 colorectal carcinoma animal model. Pharmacokinetics and biodistribution studies were done in Sprague Dawley rats. Results: PTX was encapsulated at the core of approximately 78 nm PaxSLN. PaxSLN targeted aldehyde dehydrogenase overexpressing cells. Its oral bioavailability was approximately 95% and chemotherapeutic efficacy was better than Taxol® and nab-PTX. Conclusion: A novel oral nanoformulation of PTX was developed.
Keyphrases
- alcohol consumption
- induced apoptosis
- computed tomography
- magnetic resonance imaging
- photodynamic therapy
- magnetic resonance
- high throughput
- cell cycle arrest
- mass spectrometry
- cell proliferation
- positron emission tomography
- oxidative stress
- high resolution
- molecularly imprinted
- dual energy
- image quality
- chemotherapy induced
- light emitting